Market Overview

Goldman Sachs Upgrades Vertex Pharmaceuticals To Buy

Related VRTX
Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering
44 Biggest Movers From Friday
Playing The Expectations Game In Biotech (Seeking Alpha)

Analysts at Goldman Sachs upgraded Vertex Pharmaceuticals (NASDAQ: VRTX) from Neutral to Buy.

The target price for Vertex Pharmaceuticals has been raised from $109 to $131.

Vertex Pharma shares have gained 16.00% over the past 52 weeks, while the S&P 500 index has surged 20.10% in the same period.

Vertex Pharmaceuticals' shares rose 0.22% to $95.25 in pre-market trading.

Latest Ratings for VRTX

Apr 2018Morgan StanleyMaintainsOverweightOverweight
Mar 2018Maxim GroupMaintainsBuyBuy
Feb 2018JMP SecuritiesMaintainsMarket OutperformMarket Outperform

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings

Posted-In: Goldman SachsUpgrades Analyst Ratings


Related Articles (VRTX)

View Comments and Join the Discussion!